Sort   by:  
 Page size 
ProteomicsPharmacological weight loss with incretin-based therapies does not result in a disproportionate loss of muscle mass or function in obese mice and humans
The new generation of incretin-based therapies are potent anti-obesity medications (AOMs) that offer the first non-surgical treatment for 936 million patients globally suffering from being overweight or obese (Federation, 2025). However, clinical data suggest that incretin-mimetics could cause a dis...
ORGANISM(S): Mus musculus (Mouse) 
2026-01-22 | PXD070915 | Pride
Muscle  glp-1  incretins  immobilization  weight loss  wasting  atrophy 
Sort   by:  
 Page size